ICD-10 Code C23: Malignant neoplasm of gallbladder

Key Takeaways

ICD-10 Code C23 is the billable ICD-10-CM code for malignant neoplasm of the gallbladder, effective October 1, 2025 for FY2026.

Pathology confirmation of malignancy is required before assigning C23. Do not code from symptoms alone.

C23 is distinct from adjacent biliary codes C24.0 (bile duct) and C24.1 (ampulla of Vater). Site specificity matters.

Practice management software like Pabau helps oncology billers attach ICD-10 codes accurately and reduce claim denials.

ICD-10 Code C23 is the billable ICD-10-CM diagnosis code for malignant neoplasm of the gallbladder, within the C15-C26 block for digestive-organ malignancies. Gallbladder cancer is diagnosed in roughly 5,000 Americans each year, and getting the code right depends on understanding both its clinical scope and its documentation requirements.

This reference covers the code’s classification, documentation standards, related codes, DRG groupings, common CPT pairings, and the crosswalk to its ICD-9-CM predecessor.

For oncology teams and billers working with a practice management software platform, C23 is one of the more straightforward primary malignancy codes once you know the site boundaries and sequencing rules. The sections below cover everything coders need to assign, document, and bill this code correctly.

ICD-10 Code C23: Definition and billable status

C23 is a billable, specific ICD-10-CM diagnosis code. Its full clinical description is Malignant neoplasm of gallbladder. The code classifies primary gallbladder cancer for diagnosis and reimbursement purposes across outpatient, inpatient, and professional-service claims.

C23 covers only the gallbladder itself. The bile ducts, ampulla of Vater, and liver each have separate codes. Site-specific coding is a requirement, not a suggestion: assigning C23 to a bile duct primary or vice versa produces a misclassified claim and a documentation mismatch against the pathology report.

According to the CMS ICD-10-CM code files, C23 became effective October 1, 2025 and has not changed in description since its adoption in the ICD-10-CM transition.

Code classification and ICD-10 hierarchy

ICD-10 Code C23 sits within a well-defined hierarchy. Understanding its parent categories helps coders navigate adjacent codes and reduces misassignment. The ICD-10-CM code structure organizes every diagnosis into chapters, blocks, and specific codes.

C23 has no subcategory codes. There is no C23.0, C23.1, or further subdivision. The code is complete at three characters, which makes it both specific and immediately billable without further extension. This differs from codes like C22 (liver) and C24 (biliary tract), which have multiple subcategories requiring additional specificity.

Clinical description of gallbladder cancer

Gallbladder cancer is a malignant neoplasm arising from the epithelium of the gallbladder wall. Adenocarcinoma accounts for roughly 85-90% of cases. The disease often presents late because the gallbladder is not easily visualized, and many cases are incidentally discovered during cholecystectomy for gallstone disease.

• Primary vs. secondary malignancy: C23 is for primary gallbladder cancer only. Metastatic disease spreading to the gallbladder from another primary site uses a secondary neoplasm code (C78.89 or similar), not C23.
• Pathology requirement: Coders must have a pathology or biopsy report confirming malignancy before assigning C23. Radiologic suspicion or clinical impression alone does not justify the code under ICD-10-CM Official Guidelines Section I.C.2.
• Histological types included: Adenocarcinoma, squamous cell carcinoma, and other gallbladder-origin histologies all fall under C23 when the primary site is the gallbladder.
• Stage is not captured in C23: The code itself carries no staging information. TNM or AJCC staging is documented separately in the medical record but does not alter the C23 assignment.

Documentation requirements for ICD-10 Code C23

Four elements must appear in the medical record before a coder assigns C23. Missing any one of them creates audit exposure and supports a denial on appeal. Strong documentation standards apply uniformly across all malignancy codes, and C23 is no exception. Consistent oncology documentation workflows from the point of patient intake forward make this much easier to achieve.

• Confirmed malignancy: For inpatient encounters, if gallbladder cancer is still documented as probable, suspected, possible, or rule-out at discharge, code it as confirmed, per ICD-10-CM Official Guidelines Section II.H. For outpatient and professional-service encounters, do not code an uncertain diagnosis as confirmed. Code the signs, symptoms, or findings that prompted the visit instead, per Section IV.H.
• Site specificity: Documentation must specify the gallbladder as the primary site, not merely “abdominal malignancy” or “hepatobiliary cancer.”
• Pathology report reference: The clinical note should reference the biopsy or surgical specimen report. Coders should query the physician if the note lacks a pathology reference for a malignancy code.
• Laterality: C23 has no laterality component (the gallbladder is a single midline organ), so no laterality modifier is required.

Related ICD-10 codes for gallbladder cancer and biliary tract

The C15-C26 block covers malignant neoplasms of all digestive organs, from esophageal tumors at the top of the tract down to a malignant neoplasm of the rectum (C20) at its end. Coders working with C23 regularly encounter adjacent codes in the hepatobiliary group. Understanding these distinctions prevents the most common misassignment: coding C23 when the primary site is actually the bile duct. Related biliary and pancreatic disorders under K87 follow the same site-specificity logic as the malignancy chapters, and the same anatomic precision governs the salivary glands at the very start of the digestive tract, where a malignant neoplasm of the parotid gland (C07) is coded to its own site rather than a generic head-and-neck category.

Cholangiocarcinoma is the most frequently confused condition. Intrahepatic cholangiocarcinoma maps to C22.1, not C23. Extrahepatic cholangiocarcinoma (common bile duct) maps to C24.0. Only cancer originating in the gallbladder itself maps to C23. When the pathology report is ambiguous about the site of origin, query the physician rather than defaulting to C23.

Associated symptom and complication codes

Gallbladder cancer often presents with symptoms that require separate coding. ICD-10-CM Official Guidelines Section I.C.18.b permits additional codes for signs and symptoms when they are clinically significant and not routinely associated with the primary diagnosis. For C23, the most common additional codes are:

Sequencing rule: C23 is always the principal or primary diagnosis when the encounter is for treatment of gallbladder cancer. Symptom codes follow. Do not lead with a symptom code and list C23 as secondary when the underlying cancer is known and is the reason for the visit.

DRG groupings associated with C23

For hospital inpatient claims, C23 maps to several Medicare Severity Diagnosis Related Groups (MS-DRGs) within MDC 07 (diseases and disorders of the hepatobiliary system and pancreas), depending on the presence of major complications/comorbidities (MCC) or complications/comorbidities (CC). Reimbursement amounts vary by payer, fiscal year, and geographic wage index. The figures below reflect general MS-DRG assignment logic, not specific dollar amounts.

When C23 is the principal diagnosis and a surgical procedure (such as cholecystectomy) is performed, the case may group to a surgical DRG rather than a medical DRG. The presence of open vs. laparoscopic cholecystectomy affects DRG assignment significantly. Coders should verify DRG grouping through their encoder after all procedure codes are assigned.

CPT codes commonly paired with ICD-10 C23

C23 is the diagnosis code; CPT codes capture the procedures performed. The most common pairings occur in surgical, pathology, and oncology service contexts. According to the AAPC ICD-10-CM code reference, digestive malignancy codes including C23 pair with both surgical and supportive-care CPT codes depending on the treatment phase.

Streamline oncology billing with Pabau

Pabau's claims management tools help oncology billing teams attach ICD-10 codes accurately, capture pathology documentation, and reduce claim denials on complex codes like C23.

Book a demo

Common coding mistakes to avoid with C23

Gallbladder cancer codes generate audit activity because of the close anatomical proximity of several distinct codes. These errors appear consistently in coder quality reviews and payer audits. Applying compliant billing practices from the point of encounter documentation prevents the most expensive downstream corrections.

• Using C23 without pathology confirmation: Assign C23 only when a pathology or biopsy report confirms malignancy. Clinical suspicion, imaging findings, or a referring physician’s note are not sufficient in isolation. This is the most frequently cited audit finding for this code.
• Confusing C23 with C24.x biliary codes: Tumors arising in the cystic duct, common bile duct, or ampulla of Vater are not gallbladder primaries. Check the pathology report for the specific anatomic site before selecting between C23 and C24.0.
• Incorrect sequencing of symptom codes: When the reason for the encounter is gallbladder cancer treatment, C23 is always the principal diagnosis. Placing jaundice (R17) or abdominal pain (R10.x) as the principal code when cancer is the confirmed diagnosis is a sequencing error.
• Coding secondary metastatic disease as C23: If cancer has spread to the gallbladder from a primary site elsewhere (for example, from the colon or stomach), use the appropriate secondary neoplasm code, not C23. C23 is for primary gallbladder malignancies only.
• Failing to update to the current edition: Always verify against the current FY edition. C23 has been effective since October 1, 2025 for FY2026. Submissions against an outdated codebook cause avoidable rejections.

ICD-10 C23 to ICD-9-CM crosswalk

For legacy system queries, claims appeals involving older dates of service, or research using historical Medicare data, C23 maps to a single ICD-9-CM code. The CMS General Equivalence Mappings (GEMs) confirm this as a one-to-one forward mapping with no alternatives.

The ICD-9-CM description is identical. This crosswalk is relevant for practices filing appeals on claims with dates of service before October 1, 2015, or for researchers reconciling cancer registry data across the ICD-9-to-ICD-10 transition period. Use the CDC/NCHS ICD-10-CM web tool to verify current code status and confirm GEM mappings for any code in the C15-C26 block.

How practice management software supports C23 coding

Oncology coding for a code like C23 involves multiple documentation touchpoints: the initial clinical note, the pathology report, the treatment encounter, and the claims submission.

The chain often starts earlier than the cancer diagnosis itself, when a primary care practice works up vague right-upper-quadrant pain, or a wellness clinic flags an incidental gallbladder finding on routine imaging. A missed detail at that stage carries through to the eventual C23 claim.

Pabau’s claims management software gives billing teams a structured workflow for attaching diagnosis codes to encounters at the time of service, not as a post-hoc administrative step. The platform’s digital forms capture clinical documentation, including pathology references, at intake, so the record supporting a C23 diagnosis is complete before the claim goes out.

Patient records are stored alongside the encounter in a single patient record management system, so coders reviewing documentation for C23 assignment have everything in one place without toggling between systems.

For practices managing oncology patients alongside a broader service mix, HIPAA-compliant clinical documentation and EHR integration for oncology workflows reduce the administrative overhead that makes complex code sets harder to get right consistently.

Conclusion

C23 is a straightforward code once you know the site boundaries: gallbladder primary only, pathology confirmation required, no subcategory extensions needed. The coding errors that generate denials and audits on this code almost always come down to site confusion with C24.x or sequencing mistakes when symptoms are present alongside a confirmed cancer diagnosis.

Pabau’s integrated claims management software links pathology documentation, encounter notes, and diagnosis code assignment in one workflow, making it easier for billing teams to meet the documentation standard C23 requires. To see how Pabau handles oncology billing workflows, book a demo.

Continue your research

Comparing site-specificity rules for another head and neck malignancy? C13.0 applies the same anatomic-precision logic to the postcricoid region.

Need the same site-boundary logic for a chest malignancy? C33 covers malignant neoplasm of the trachea and its own adjacent-code confusion risks.

Working through another primary-site-only oncology code? C04.9 covers malignant neoplasm of the floor of the mouth, unspecified.

Frequently Asked Questions